Value Add VC has tracked 90 Health & Biotech venture rounds in 2026 totaling $7.4B, including 13 rounds ($777M) in Q4 2026. Ranked below: the biggest rounds, the companies that raised the most in 2026 and the ones with the highest reported valuations, and the most active lead investors.
Biotech, healthcare and health-tech startups, from drug discovery to care delivery. Private companies only; rounds tracked by Value Add VC, not a market total.
Methodology
Rounds tracked by Value Add VC from filings, wire releases and news outlets — not a total for the whole market or a complete list of every Health & Biotech company. Data window: 2026 year-to-date for the biggest rounds, the companies that raised the most, and lead-investor rankings. Companies by valuation show each company's latest reported valuation (since mid-2025) — an older figure is left off rather than shown as current.
Ranked by dollar amount (rounds, companies by funding), by latest reported figure (companies by valuation), and by number of tracked deals led (investors). Public companies, debt, fund closes, acquisitions and unverified/rumored rounds are excluded.
Last updated 2026-10-14. Missing a company or round? Submit it →
| # | Date | Company | Stage | Amount | Led by | Source |
|---|---|---|---|---|---|---|
| 1 | Oct 13, 2026 | Souffle Therapeutics | Series B | $135M | — | FinancialContent |
| 2 | Oct 6, 2026 | General Medicine | Series B | $120M | Andreessen Horowitz | PR Newswire |
| 3 | Oct 11, 2026 | TriGemX Bio | Undisclosed | $94M | TCGX | Pulse 2.0 |
| 4 | Oct 13, 2026 | Suki | Series E | $90M | — | FinancialContent (Business Wire) |
| 5 | Oct 6, 2026 | KymaThera | Series B | $80M | — | Pulse2.com |
| 6 | Oct 6, 2026 | Multiply Labs | Series B | $75M | — | Business Wire |
| 7 | Oct 10, 2026 | Atrium Therapeutics | Undisclosed | $50M | — | Pulse 2.0 |
| 8 | Oct 7, 2026 | Healthleap | Seed + Series A | $38M | Sequoia Capital, First Round Capital | TechCrunch |
| 9 | Oct 6, 2026 | Vitalize | Series A | $31M | — | Pulse2.com |
| 10 | Oct 7, 2026 | WhiteLab Genomics | Series B | $26M | — | Pulse 2.0 |
| 11 | Oct 8, 2026 | AblePay Health | Series A | $20M | F-Prime Capital | Pulse 2.0 |
| 12 | Oct 13, 2026 | MakeO | Undisclosed | $10M | — | e27 |
| 13 | Oct 10, 2026 | Vinci Pharmaceuticals | Series A | $8M | — | Pulse 2.0 |
| # | Company | 2026 tracked funding | Tracked rounds | Latest round |
|---|---|---|---|---|
| 1 | Ollin Biosciences | $486M | 2 | Jun 25, 2026 |
| 2 | Chai Discovery | $400M | 1 | Jul 14, 2026 |
| 3 | Enveda Biosciences | $311M | 1 | Sep 23, 2026 |
| 4 | Anew Labs | $290M | 1 | Sep 16, 2026 |
| 5 | Encoded Therapeutics | $275M | 1 | Sep 9, 2026 |
| 6 | OpenEvidence | $250M | 1 | Sep 25, 2026 |
| 7 | Precision Neuroscience | $250M | 1 | Sep 24, 2026 |
| 8 | Scan.com | $220M | 1 | Sep 5, 2026 |
| 9 | eMed | $200M | 1 | Mar 26, 2026 |
| 10 | Osanni Bio | $190M | 1 | Jun 26, 2026 |
| 11 | Celea Therapeutics | $180M | 1 | Jul 2, 2026 |
| 12 | Fortell | $163M | 1 | Sep 16, 2026 |
| 13 | Rightway | $155M | 1 | Sep 25, 2026 |
| 14 | Basecamp Research | $140M | 1 | Sep 23, 2026 |
| 15 | Souffle Therapeutics | $135M | 1 | Oct 13, 2026 |
| # | Company | Valuation | As of | Source |
|---|---|---|---|---|
| 1 | Colossal Biosciences | $10.32B | 2025-09-18 | Colossal Biosciences |
| 2 | Commure | $7B | 2026-05-19 | Commure |
| 3 | Chai Discovery | $3.8B | 2026-07-17 | Crunchbase News |
| 4 | Function Health | $2.5B | 2025-11-19 | TechCrunch |
| 5 | Enveda Biosciences | ~$2B | 2026-09-23 | Tech Startups |
| 6 | Rightway | $1.75B | 2026-09-24 | Bloomberg |
| 7 | Precision Neuroscience | ~$1B | 2026-09-24 | GlobeNewswire |
Not enough tracked lead-investor data yet for Health & Biotech.
| # | Date | Company | Stage | Amount | Led by | Source |
|---|---|---|---|---|---|---|
| 1 | Oct 13, 2026 | MakeO | Undisclosed | $10M | — | e27 |
| 2 | Oct 13, 2026 | Souffle Therapeutics | Series B | $135M | — | FinancialContent |
| 3 | Oct 13, 2026 | Suki | Series E | $90M | — | FinancialContent (Business Wire) |
| 4 | Oct 11, 2026 | TriGemX Bio | Undisclosed | $94M | TCGX | Pulse 2.0 |
| 5 | Oct 10, 2026 | Atrium Therapeutics | Undisclosed | $50M | — | Pulse 2.0 |
| 6 | Oct 10, 2026 | Vinci Pharmaceuticals | Series A | $8M | — | Pulse 2.0 |
| 7 | Oct 8, 2026 | AblePay Health | Series A | $20M | F-Prime Capital | Pulse 2.0 |
| 8 | Oct 7, 2026 | Healthleap | Seed + Series A | $38M | Sequoia Capital, First Round Capital | TechCrunch |
| 9 | Oct 7, 2026 | WhiteLab Genomics | Series B | $26M | — | Pulse 2.0 |
| 10 | Oct 6, 2026 | General Medicine | Series B | $120M | Andreessen Horowitz | PR Newswire |
| 11 | Oct 6, 2026 | KymaThera | Series B | $80M | — | Pulse2.com |
| 12 | Oct 6, 2026 | Multiply Labs | Series B | $75M | — | Business Wire |
| 13 | Oct 6, 2026 | Vitalize | Series A | $31M | — | Pulse2.com |
| 14 | Sep 30, 2026 | Tiny Health | Series B | $33M | B Capital | The SaaS News |
| 15 | Sep 29, 2026 | BioStem Technologies | Undisclosed | $3M | — | SEC EDGAR Form D |